SOPHiA GENETICS
sophiagenetics.com
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Financials
Overview
SOPHiA GENETICS is a Swiss health technology company founded in 2011 near Lausanne. Its cloud platform analyses genomic and multimodal patient data to support cancer and rare disease diagnosis. The company is listed on Nasdaq and works with hundreds of hospitals worldwide.
News
JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms
JAK (Janus Kinase) inhibitors, such as ruxolitinib, were introduced a decade ago for treatment of myeloproliferative neoplasms (MPN). To evaluate ruxolitinib's impact on MPN clonal evolution, we interrogate a myelofibrosis patient cohort with longitudinal
Read more
Report
Celebrating 1 Year of SOPHiA DDM Homologous Recombination Deficiency (HRD) Solution!
Accelerating and empowering our customers' clinical cancer research decisions with cost-effective, accurate and fast in-house results. This week is marking one year from the official launch of the SOPHiA DDM Homologous Recombination Deficiency (HRD) Solut
Read more
Report
In the Face of Rare Disease: The Inspiring Story of Brooklynn
This February 28th, we at SOPHiA GENETICS can't help but feel a profound sense of connection with those living with rare diseases. Rare Disease Day isn't just about raising awareness - it's about celebrating the incredible individuals who have touched our
Read more
Report
International Childhood Cancer Day 2023: Better survival is achievable!
About Childhood Cancer According to the World Health Organization, over 400,000 children and adolescents (0-19 years old) are diagnosed with cancer (1), while every 3 minutes, a child loses the battle with the disease. Although childhood cancer incidence
Read more
Report
How the Future of Genomic Analysis is Already Furthering Breast Cancer Research
Breast cancer patients are faced with varying challenges including genetic makeup, financial circumstances, and health care access. For this reason, researchers and technology developers are working hard to evolve options, to give patients around the worl
Read more
Report
Pro access
Upgrade to see all 11 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.